12:00 AM
May 26, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GI-5005: Completed Phase II enrollment

GlobeImmune completed enrollment of 120 patients with chronic HCV genotype 1 infection in an open-label, international Phase II trial evaluating pegylated interferon plus ribavirin with or...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >